Published in J Biol Chem on December 14, 2010
Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal (2012) 2.05
The orphan nuclear receptor NR4A1 (Nur77) regulates oxidative and endoplasmic reticulum stress in pancreatic cancer cells. Mol Cancer Res (2014) 1.01
Cancer prevention with promising natural products: mechanisms of action and molecular targets. Anticancer Agents Med Chem (2012) 1.01
Snake venom toxin from Vipera lebetina turanica induces apoptosis of colon cancer cells via upregulation of ROS- and JNK-mediated death receptor expression. BMC Cancer (2012) 1.00
Resveratrol suppresses constitutive activation of AKT via generation of ROS and induces apoptosis in diffuse large B cell lymphoma cell lines. PLoS One (2011) 0.93
Ursolic acid inhibits proliferation and induces apoptosis of cancer cells in vitro and in vivo. J Biomed Biotechnol (2011) 0.89
Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: evidence for the role of c-Jun N-terminal kinase activation. Cell Cycle (2012) 0.89
Medicarpin, a legume phytoalexin sensitizes myeloid leukemia cells to TRAIL-induced apoptosis through the induction of DR5 and activation of the ROS-JNK-CHOP pathway. Cell Death Dis (2014) 0.88
A pentacyclic triterpene natural product, ursolic acid and its prodrug US597 inhibit targets within cell adhesion pathway and prevent cancer metastasis. Oncotarget (2015) 0.87
Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy. Exp Biol Med (Maywood) (2015) 0.86
Sub-toxic dose of apigenin sensitizes HepG2 cells to TRAIL through ERK-dependent up-regulation of TRAIL receptor DR5. Mol Cells (2012) 0.82
Prevention and Treatment of Colorectal Cancer by Natural Agents From Mother Nature. Curr Colorectal Cancer Rep (2013) 0.80
Phosphorylated IκBα predicts poor prognosis in activated B-cell lymphoma and its inhibition with thymoquinone induces apoptosis via ROS release. PLoS One (2013) 0.80
Evolution in medicinal chemistry of ursolic acid derivatives as anticancer agents. Eur J Med Chem (2015) 0.80
Ursolic acid induces neural regeneration after sciatic nerve injury. Neural Regen Res (2013) 0.80
Ursolic acid inhibits the growth of human pancreatic cancer and enhances the antitumor potential of gemcitabine in an orthotopic mouse model through suppression of the inflammatory microenvironment. Oncotarget (2016) 0.80
Induction of cell cycle arrest and apoptosis in caspase-3 deficient MCF-7 cells by Dillenia suffruticosa root extract via multiple signalling pathways. BMC Complement Altern Med (2014) 0.80
Ursolic acid attenuates temozolomide resistance in glioblastoma cells by downregulating O(6)-methylguanine-DNA methyltransferase (MGMT) expression. Am J Transl Res (2016) 0.79
Ursolic acid synergistically enhances the therapeutic effects of oxaliplatin in colorectal cancer. Protein Cell (2016) 0.79
Zyflamend sensitizes tumor cells to TRAIL-induced apoptosis through up-regulation of death receptors and down-regulation of survival proteins: role of ROS-dependent CCAAT/enhancer-binding protein-homologous protein pathway. Antioxid Redox Signal (2011) 0.79
A phase I trial to evaluate the multiple-dose safety and antitumor activity of ursolic acid liposomes in subjects with advanced solid tumors. Biomed Res Int (2015) 0.76
A humanized leucine zipper-TRAIL hybrid induces apoptosis of tumors both in vitro and in vivo. PLoS One (2015) 0.76
Induction of Apoptosis and Reduction of Endogenous Glutathione Level by the Ethyl-Acetate Soluble Fraction of the Methanol Extract of the Roots of Potentilla fulgens in Cancer Cells. PLoS One (2015) 0.76
Down-Regulation of AKT Signalling by Ursolic Acid Induces Intrinsic Apoptosis and Sensitization to Doxorubicin in Soft Tissue Sarcoma. PLoS One (2016) 0.76
Polymeric mechanical amplifiers of immune cytokine-mediated apoptosis. Nat Commun (2017) 0.75
Three new C-27-carboxylated-lupane-triterpenoid derivatives from Potentilla discolor Bunge and their in vitro antitumor activities. PLoS One (2017) 0.75
Pomolic acid induces apoptosis in SK-OV-3 human ovarian adenocarcinoma cells through the mitochondrial-mediated intrinsic and death receptor-induced extrinsic pathways. Oncol Lett (2012) 0.75
Structural and bioactive studies of terpenes and cyclopeptides from the Genus Rubia. Chem Cent J (2013) 0.75
ERK mediated upregulation of death receptor 5 overcomes the lack of p53 functionality in the diaminothiazole DAT1 induced apoptosis in colon cancer models: efficiency of DAT1 in Ras-Raf mutated cells. Mol Cancer (2016) 0.75
MDL-12330A potentiates TRAIL-induced apoptosis in gastric cancer cells through CHOP-mediated DR5 upregulation. Korean J Physiol Pharmacol (2017) 0.75
Andrographolide induces apoptotic and non-apoptotic death and enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in gastric cancer cells. Oncol Lett (2017) 0.75
Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity (1995) 10.59
Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol (2003) 10.29
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med (1999) 9.78
Inhibition of death receptor signals by cellular FLIP. Nature (1997) 9.58
Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest (1999) 7.69
An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science (1997) 6.10
Pharmacology of oleanolic acid and ursolic acid. J Ethnopharmacol (1995) 4.91
CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells. J Biol Chem (2004) 3.70
Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther (2005) 3.27
Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell (2004) 3.14
Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med (2004) 2.71
Reactive oxygen species and programmed cell death. Trends Biochem Sci (1996) 2.68
Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ (2004) 2.17
Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene (2002) 1.97
Novel triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2) in mouse macrophages. Cancer Res (1998) 1.80
Inhibition of skin tumorigenesis by rosemary and its constituents carnosol and ursolic acid. Cancer Res (1994) 1.80
Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene (2000) 1.79
Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene (2000) 1.69
Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cells. Mol Cancer Res (2007) 1.61
Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res (1999) 1.56
Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products. Clin Cancer Res (2008) 1.55
TRAIL receptor-mediated JNK activation and Bim phosphorylation critically regulate Fas-mediated liver damage and lethality. J Clin Invest (2006) 1.55
Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol (2006) 1.52
Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant hepatoma cells to TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of DR5. Cancer Res (2006) 1.47
Zerumbone enhances TRAIL-induced apoptosis through the induction of death receptors in human colon cancer cells: Evidence for an essential role of reactive oxygen species. Cancer Res (2009) 1.43
Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. Cancer Res (2005) 1.32
Reactive oxygen species mediate oridonin-induced HepG2 apoptosis through p53, MAPK, and mitochondrial signaling pathways. J Pharmacol Sci (2008) 1.30
Inhibitory effect of ursolic acid on B16 proliferation through cell cycle arrest. Cancer Lett (1996) 1.28
Ursolic acid triggers apoptosis and Bcl-2 downregulation in MCF-7 breast cancer cells. Cancer Invest (2009) 1.24
Proliferative inhibition, cell-cycle dysregulation, and induction of apoptosis by ursolic acid in human non-small cell lung cancer A549 cells. Life Sci (2004) 1.24
Regulation of TRAIL expression by the phosphatidylinositol 3-kinase/Akt/GSK-3 pathway in human colon cancer cells. J Biol Chem (2002) 1.24
Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through reactive oxygen species-mediated upregulation of death receptor 5 (DR5). Carcinogenesis (2005) 1.23
Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L). Cancer Res (2002) 1.20
Ursolic acid inhibits cyclooxygenase-2 transcription in human mammary epithelial cells. Cancer Res (2000) 1.19
LY303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells via hydrogen peroxide-mediated mitogen-activated protein kinase activation and up-regulation of death receptors. Cancer Res (2009) 1.16
Inhibition by rosemary and carnosol of 7,12-dimethylbenz[a]anthracene (DMBA)-induced rat mammary tumorigenesis and in vivo DMBA-DNA adduct formation. Cancer Lett (1996) 1.16
Quercetin sensitizes human hepatoma cells to TRAIL-induced apoptosis via Sp1-mediated DR5 up-regulation and proteasome-mediated c-FLIPS down-regulation. J Cell Biochem (2008) 1.16
Effects of ursolic acid and oleanolic acid on human colon carcinoma cell line HCT15. World J Gastroenterol (2002) 1.13
A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells. Leukemia (2003) 1.12
Garcinol potentiates TRAIL-induced apoptosis through modulation of death receptors and antiapoptotic proteins. Mol Cancer Ther (2010) 1.10
Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance. Int J Oncol (2000) 1.09
Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. Oncogene (2000) 1.07
Ursolic acid-induced down-regulation of MMP-9 gene is mediated through the nuclear translocation of glucocorticoid receptor in HT1080 human fibrosarcoma cells. Oncogene (1998) 1.06
Triterpenes augment the inhibitory effects of anticancer drugs on growth of human esophageal carcinoma cells in vitro and suppress experimental metastasis in vivo. Int J Cancer (2009) 1.06
Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. Prostate (2002) 1.06
Ursolic acid attenuates oxidative stress-mediated hepatocellular carcinoma induction by diethylnitrosamine in male Wistar rats. Asian Pac J Cancer Prev (2009) 1.04
Ursolic acid induces apoptosis through mitochondrial intrinsic pathway and caspase-3 activation in M4Beu melanoma cells. Int J Cancer (2005) 1.04
Induction of apoptosis by ursolic acid through activation of caspases and down-regulation of c-IAPs in human prostate epithelial cells. Int J Oncol (2000) 1.02
Upregulation of DR5 by proteasome inhibitors potently sensitizes glioma cells to TRAIL-induced apoptosis. FEBS J (2008) 1.01
The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis. Mol Ther (2000) 1.01
Apoptotic activity of ursolic acid may correlate with the inhibition of initiation of DNA replication. Int J Cancer (2000) 1.01
Differential effects of several phytochemicals and their derivatives on murine keratinocytes in vitro and in vivo: implications for skin cancer prevention. Carcinogenesis (2009) 0.98
Intracellular mechanisms of TRAIL and its role in cancer therapy. Mol Cell Biol Res Commun (2000) 0.97
Ursolic acid induces PC-3 cell apoptosis via activation of JNK and inhibition of Akt pathways in vitro. Mol Carcinog (2010) 0.95
Intracellular Ca2+ release mediates ursolic acid-induced apoptosis in human leukemic HL-60 cells. Int J Cancer (1997) 0.94
Mother Nature's gifts to diseases of man: the impact of natural products on anti-infective, anticholestemics and anticancer drug discovery. Prog Drug Res (2008) 0.94
TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8. Lung Cancer (2008) 0.85
Cyclic adenosine monophosphate inhibits ursolic acid-induced apoptosis via activation of protein kinase A in human leukaemic HL-60 cells. Pharmacol Toxicol (2000) 0.84
Synergistic cytotoxicity through the activation of multiple apoptosis pathways in human glioma cells induced by combined treatment with ionizing radiation and tumor necrosis factor-related apoptosis-inducing ligand. J Neurosurg (2007) 0.82
TRAIL-R2 is not correlated with p53 status and is rarely mutated in non-small cell lung cancer. Anticancer Res (2001) 0.81
Potential mechanisms of resistance to TRAIL/Apo2L-induced apoptosis in human promyelocytic leukemia HL-60 cells during granulocytic differentiation. Cell Death Differ (2000) 0.80
Bioavailability of curcumin: problems and promises. Mol Pharm (2007) 8.72
Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med (2010) 7.31
Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol (2007) 5.13
Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res (2008) 4.29
Nuclear factor-kappaB: its role in health and disease. J Mol Med (Berl) (2004) 4.01
Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett (2008) 3.61
Cancer is a preventable disease that requires major lifestyle changes. Pharm Res (2008) 3.28
Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett (2008) 3.14
Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol (2008) 2.95
Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J (2009) 2.89
Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways. Mol Pharmacol (2007) 2.70
Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol (2005) 2.62
Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev (2010) 2.57
Inhibiting NF-κB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta (2010) 2.55
Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol (2003) 2.44
"Spicing up" of the immune system by curcumin. J Clin Immunol (2007) 2.43
Curcumin: getting back to the roots. Ann N Y Acad Sci (2005) 2.42
Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J (2012) 2.42
Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol (2002) 2.27
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24
Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol (2003) 2.22
Reactive oxygen intermediates in TNF signaling. Mol Immunol (2002) 2.20
Growth properties of cardiac stem cells are a novel biomarker of patients' outcome after coronary bypass surgery. Circulation (2013) 2.19
Nuclear factor-kappaB activation: from bench to bedside. Exp Biol Med (Maywood) (2008) 2.19
Retracted Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol (2009) 2.12
Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle (2008) 2.10
Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal (2012) 2.05
Hydrogen peroxide activates NF-kappa B through tyrosine phosphorylation of I kappa B alpha and serine phosphorylation of p65: evidence for the involvement of I kappa B alpha kinase and Syk protein-tyrosine kinase. J Biol Chem (2003) 2.05
Transcription factor NF-kappaB: a sensor for smoke and stress signals. Ann N Y Acad Sci (2005) 2.05
NF-kappaB and cancer: how intimate is this relationship. Mol Cell Biochem (2009) 2.03
Role of curcumin in cancer therapy. Curr Probl Cancer (2007) 2.00
Cancer prevention with natural compounds. Semin Oncol (2010) 1.98
Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res (2007) 1.98
Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol (2005) 1.94
A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. Clin Cancer Res (2006) 1.92
TNF: a master switch for inflammation to cancer. Front Biosci (2008) 1.91
Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem (2003) 1.91
Anticancer potential of silymarin: from bench to bed side. Anticancer Res (2007) 1.91
Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res (2004) 1.90
Role of chemopreventive agents in cancer therapy. Cancer Lett (2004) 1.88
Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res (2008) 1.88
Necrosis and glioblastoma: a friend or a foe? A review and a hypothesis. Neurosurgery (2002) 1.83
Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. Cancer Res (2006) 1.82
Tocotrienols, the vitamin E of the 21st century: its potential against cancer and other chronic diseases. Biochem Pharmacol (2010) 1.82
Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis (2002) 1.79
Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res (2002) 1.78
Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis (2007) 1.78
Inositol 1, 4, 5-trisphosphate receptors and human left ventricular myocytes. Circulation (2013) 1.73
Retracted Cyclodextrin-complexed curcumin exhibits anti-inflammatory and antiproliferative activities superior to those of curcumin through higher cellular uptake. Biochem Pharmacol (2010) 1.72
Cancer drug discovery by repurposing: teaching new tricks to old dogs. Trends Pharmacol Sci (2013) 1.72
Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol (2012) 1.72
Genetic deletion of glycogen synthase kinase-3beta abrogates activation of IkappaBalpha kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor. J Biol Chem (2004) 1.66
Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res (2008) 1.63
Cigarette smoke condensate activates nuclear transcription factor-kappaB through phosphorylation and degradation of IkappaB(alpha): correlation with induction of cyclooxygenase-2. Carcinogenesis (2002) 1.63
Multitargeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep (2011) 1.62
Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer (2010) 1.62
Age-associated defects in EphA2 signaling impair the migration of human cardiac progenitor cells. Circulation (2013) 1.61
Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cells. Mol Cancer Res (2007) 1.61
RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. J Biol Chem (2004) 1.61
Natural products as a gold mine for arthritis treatment. Curr Opin Pharmacol (2007) 1.59
Targeting nuclear factor-kappa B activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis. Mol Cancer Res (2008) 1.58
Nuclear factor-kappaB activation: a question of life or death. J Biochem Mol Biol (2002) 1.58
A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo. Mol Cancer Ther (2010) 1.58
Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products. Clin Cancer Res (2008) 1.55
Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. Mol Cancer Ther (2008) 1.55
Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-kappaB activation through inhibition of IkappaBalpha kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1. Carcinogenesis (2003) 1.54
Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Oncogene (2002) 1.54
Nuclear factor-kappaB: a friend or a foe in cancer? Biochem Pharmacol (2004) 1.53
Identification of novel anti-inflammatory agents from Ayurvedic medicine for prevention of chronic diseases: "reverse pharmacology" and "bedside to bench" approach. Curr Drug Targets (2011) 1.53
Concern Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappaB signaling pathway. Blood (2007) 1.52
A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications. J Immunol (2007) 1.52
Role of pro-oxidants and antioxidants in the anti-inflammatory and apoptotic effects of curcumin (diferuloylmethane). Free Radic Biol Med (2007) 1.51
Aldose reductase mediates mitogenic signaling in vascular smooth muscle cells. J Biol Chem (2002) 1.51
The role of chalcones in suppression of NF-κB-mediated inflammation and cancer. Int Immunopharmacol (2010) 1.50
Resveratrol addiction: to die or not to die. Mol Nutr Food Res (2009) 1.50
Pomegranate juice, total pomegranate ellagitannins, and punicalagin suppress inflammatory cell signaling in colon cancer cells. J Agric Food Chem (2006) 1.49
Multi-targeted therapy by curcumin: how spicy is it? Mol Nutr Food Res (2008) 1.47
Curcumin, a component of turmeric: from farm to pharmacy. Biofactors (2013) 1.47
From ancient medicine to modern medicine: ayurvedic concepts of health and their role in inflammation and cancer. J Soc Integr Oncol (2007) 1.47
Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. Cancer Res (2008) 1.45
Gamma-tocotrienol inhibits nuclear factor-kappaB signaling pathway through inhibition of receptor-interacting protein and TAK1 leading to suppression of antiapoptotic gene products and potentiation of apoptosis. J Biol Chem (2006) 1.45
Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer (2006) 1.45
Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kappaB signaling. Int J Cancer (2004) 1.44
Zerumbone enhances TRAIL-induced apoptosis through the induction of death receptors in human colon cancer cells: Evidence for an essential role of reactive oxygen species. Cancer Res (2009) 1.43
Concern Modification of the cysteine residues in IkappaBalpha kinase and NF-kappaB (p65) by xanthohumol leads to suppression of NF-kappaB-regulated gene products and potentiation of apoptosis in leukemia cells. Blood (2008) 1.42
Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int J Cancer (2010) 1.42